7-Deaza-2'-deoxyguanosine
[CAS# 86392-75-8]

Identification

• Classification: Biochemical >> Nucleoside drugs >> Deoxynucleotides and their analogues
• Name: 7-Deaza-2'-deoxyguanosine
• Synonyms: 2-Amino-7-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
• Protein Sequence: N
• Molecular Formula: C₁₁H₁₄N₄O₄
• Molecular Weight: 266.25
• CAS Registry Number: 86392-75-8
• SMILES: C1[C@@H]([C@H](O[C@H]1N2C=CC3=C2N=C(NC3=O)N)CO)O

Properties

• Solubility: Very slightly soluble (0.17 g/L) (25 ºC), Calc.^*
• Density: 1.90±0.1 g/cm³ (20 ºC 760 Torr), Calc.^*
• Melting point: 262-265 ºC^**
• Index of Refraction: 1.834, Calc.^*
• Boiling Point: 621.4±65.0 ºC (760 mmHg), Calc.^*
• Flash Point: 329.6±34.3 ºC, Calc.^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2015 ACD/Labs)

^** Seela, Frank; Acta Crystallographica, Section C: Crystal Structure Communications 2005, VC61(3), Po151-o153.

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H302-H315-H319-H332-H335
• Precautionary Statements: P261-P280-P305+P351+P338

Discovory and Applicatios

7-Deaza-2'-deoxyguanosine is a modified nucleoside analogue that has garnered attention in both antiviral research and the study of nucleic acid biochemistry. This compound is a structural analogue of 2'-deoxyguanosine, where the nitrogen atom at position 7 of the purine ring is replaced by a carbon atom. This modification alters the base-pairing properties and stability of the nucleoside, making it a valuable tool in molecular biology and antiviral drug design.

The discovery of 7-deaza-2'-deoxyguanosine was part of ongoing research aimed at modifying nucleoside analogues to improve their efficacy and specificity in inhibiting DNA synthesis. It was initially synthesized in the 1990s as part of a broader effort to develop nucleoside analogues that could act as inhibitors of DNA polymerases, especially for retroviral and cellular DNA replication. The modification at position 7 of the guanine base was designed to reduce the compound's ability to form base pairs with cytosine, potentially disrupting DNA replication in a controlled manner.

In terms of its biological application, 7-deaza-2'-deoxyguanosine has been primarily studied for its effects on nucleic acid replication processes. As a deoxyguanosine analogue, it can be incorporated into DNA strands during DNA synthesis, but it exhibits altered base-pairing properties due to the absence of the nitrogen at the 7-position. This modification can interfere with the normal replication and transcription processes, offering potential as an antiviral agent or as a tool in cancer therapy.

One of the key areas where 7-deaza-2'-deoxyguanosine has been investigated is in the inhibition of retroviruses, particularly human immunodeficiency virus (HIV). Similar to other nucleoside analogues like zidovudine and lamivudine, 7-deaza-2'-deoxyguanosine can be incorporated into the viral DNA during reverse transcription, resulting in chain termination. However, unlike conventional guanosine analogues, the modified structure of 7-deaza-2'-deoxyguanosine makes it less likely to be recognized by the reverse transcriptase enzyme, potentially limiting its activity against retroviruses compared to other nucleoside reverse transcriptase inhibitors (NRTIs).

In addition to its antiviral potential, 7-deaza-2'-deoxyguanosine has been explored for its ability to act as a research tool in the study of nucleic acid structure and function. Its incorporation into DNA allows for the investigation of how structural modifications at the purine ring affect DNA stability, replication, and repair. Researchers use 7-deaza-2'-deoxyguanosine to probe the effects of base-pairing alterations on the overall integrity of DNA molecules and to better understand the role of specific base interactions in the mechanics of DNA replication.

7-Deaza-2'-deoxyguanosine has also been considered for its potential in cancer therapy, particularly in the context of targeting cancer cells that are rapidly dividing. Nucleoside analogues like 7-deaza-2'-deoxyguanosine can inhibit DNA replication in cancer cells, which rely on rapid and unchecked DNA synthesis for growth and proliferation. By incorporating into DNA during replication, these compounds can induce replication errors or terminate the DNA chain, potentially leading to cell death or growth inhibition. However, clinical applications in cancer therapy remain limited, as other more potent nucleoside analogues have been prioritized.

While 7-deaza-2'-deoxyguanosine shows promise in these applications, it is not without challenges. Its altered base-pairing properties may reduce its efficacy in certain contexts, especially in antiviral therapy, where the correct incorporation into the viral genome is essential for chain termination. Additionally, its potential toxicity and side effects, typical of many nucleoside analogues, need to be carefully managed in therapeutic contexts.

In conclusion, 7-deaza-2'-deoxyguanosine is a modified nucleoside analogue that has applications in antiviral research, cancer therapy, and molecular biology. Its ability to interfere with DNA replication, particularly in retroviruses and cancer cells, makes it a valuable tool in drug development and scientific studies. While its use in clinical settings remains limited due to its reduced efficacy and potential side effects, its role as a research tool continues to be significant in the study of DNA replication and repair mechanisms.